United States Patent 9,693,986: Claim Scope, Vascepa Exclusivity, Litigation and Generic Entry Risk
U.S. Patent No. 9,693,986 protects cardiovascular-risk reduction using approximately 4 g/day of ethyl icosapentate, commercially marketed as Vascepa, in statin-treated patients with elevated triglycerides. The patent is a method-of-use patent, not a composition or manufacturing patent. Its broadest independent claims cover cardiovascular death and coronary revascularization, with dependent claims narrowing the patient population, treatment duration, lipid profile, concomitant therapy, dosage-unit count and clinical endpoints.
The patent’s principal commercial value was tied to Vascepa’s 2019 FDA cardiovascular-risk indication. Generic competition has substantially reduced the practical exclusivity provided by the patent because abbreviated new drug application applicants were able to pursue a label that excluded the patented cardiovascular indication.
What does U.S. Patent 9,693,986 protect?
The patent protects a clinical treatment protocol with five central limitations:
| Limitation |
Claim 1 |
Claim 19 |
| Active ingredient |
Ethyl icosapentate |
Ethyl icosapentate |
| Daily dose |
About 4 g |
About 4 g |
| Treatment duration |
At least about 2 years |
At least about 4 months |
| Baseline triglycerides |
About 135 to 500 mg/dL |
About 135 to 500 mg/dL |
| Statin therapy |
Required |
Required |
| Established cardiovascular disease |
Not expressly required |
Required |
| Protected outcome |
Cardiovascular death and/or coronary revascularization |
Cardiovascular death and/or coronary revascularization |
Claim 1 is the broader independent claim from a patient-population standpoint because it does not expressly require established cardiovascular disease. Claim 19 has a shorter minimum treatment period but requires documented cardiovascular disease.
The claims apply to a pharmaceutical composition containing ethyl icosapentate. They do not require the branded product name Vascepa, a particular capsule shell, a particular manufacturer, or a particular trade formulation.
How broad are the independent claims?
Claim 1 scope
Claim 1 requires all of the following:
- A subject receiving statin therapy.
- Administration of a composition containing about 4 g/day of ethyl icosapentate.
- Treatment for at least about two years.
- A fasting baseline triglyceride level of about 135 to 500 mg/dL.
- A reduction in the risk of cardiovascular death and/or coronary revascularization.
The claim does not expressly require a prior cardiovascular event, coronary artery disease, diabetes, or a particular LDL-C level. That creates a potentially broad subject population, although the “reducing a risk” limitation and the baseline triglyceride range remain central infringement issues.
The use of “and/or” extends the claim to a method directed to either cardiovascular death, coronary revascularization, or both. Claims 14 through 18 expand the protected clinical outcomes to elective or emergent revascularization, myocardial infarction, stroke and unstable angina.
Claim 19 scope
Claim 19 covers patients with established cardiovascular disease and requires treatment for at least about four months. Claim 20 defines qualifying disease by reference to:
- Documented coronary artery disease;
- Documented cerebrovascular disease;
- Documented carotid disease;
- Documented peripheral arterial disease; or
- A combination of those conditions.
Claim 19 is narrower than claim 1 because of the established-cardiovascular-disease requirement, but it may be commercially important because the FDA-approved cardiovascular-risk population for Vascepa includes patients with established cardiovascular disease.
What formulations are protected by U.S. Patent 9,693,986?
The patent primarily protects use of a high-purity ethyl icosapentate composition, rather than a specific dosage-form design.
| Formulation limitation |
Relevant claims |
| About 4 g/day of ethyl icosapentate |
1, 19 |
| One to four dosage units per day |
2, 21 |
| At least about 96 wt.% of all omega-3 fatty acids is ethyl icosapentate |
3, 22 |
| Pharmaceutical composition |
1, 19 and dependent claims |
| Specific capsule shell or excipient system |
Not expressly required |
Claims 3 and 22 impose a purity limitation. A competing product containing a materially lower proportion of ethyl icosapentate among total omega-3 fatty acids could fall outside those claims, although it could still implicate the independent claims if the purity limitation is absent from the asserted claim.
The patent does not independently require a particular capsule count. Claims 2 and 21 allow one to four dosage units per day, which is consistent with a four-capsule daily regimen but does not limit the independent claims to four capsules.
Which patient characteristics matter under the patent?
Claims 5, 6, 24 and 25 add specified baseline lipid ranges:
| Biomarker |
Claimed range |
| Non-HDL-C |
About 200 to 300 mg/dL |
| Total cholesterol |
About 250 to 300 mg/dL |
| VLDL-C |
About 140 to 200 mg/dL |
| HDL-C |
About 10 to 30 mg/dL |
| LDL-C |
About 40 to 100 mg/dL |
Claim 5 uses “one or more of” the listed characteristics. Claim 6 repeats the same ranges but uses “and/or,” which creates drafting ambiguity rather than a materially different clinical profile. The same structure appears in claims 24 and 25.
These claims create narrower fallback positions if the baseline triglyceride limitation alone is insufficient to establish infringement. They also create potential proof issues because infringement analysis would require reliable baseline laboratory records taken before treatment.
Does the patent require statin and ezetimibe therapy?
Yes, statin therapy is required by claims 1 and 19. Claim 7 clarifies that statin therapy may consist of a statin with optional ezetimibe.
The claims do not require:
- A specific statin;
- A particular statin dose;
- A minimum statin treatment duration;
- A specific LDL-C reduction; or
- Concomitant ezetimibe.
A product label that recommends use with statin therapy could create inducement arguments if the label also directs use within the claimed triglyceride range, dose and cardiovascular-risk population. A label that omits the cardiovascular indication may reduce, but does not necessarily eliminate, inducement exposure.
What exclusions and washout periods are claimed?
Claims 8 through 10 address background lipid-lowering and omega-3 therapy. They require that the patient has not received:
- At least 200 mg/day of niacin and/or fibrates for at least 28 days before treatment;
- Prescription omega-3 fatty acids beginning 28 days before treatment; or
- Dietary omega-3 supplements beginning 28 days before treatment.
Claims 9 and 10 extend the relevant restriction period through at least six months, one year, two years, three years, four years, five years or longer after the first administration.
These limitations are operationally significant. They require treatment-history evidence, pharmacy records, medical records or patient-history documentation. They also provide potential noninfringement arguments where a patient continued a disqualifying supplement or lipid-modifying therapy.
When does U.S. Patent 9,693,986 expire?
| Event |
Date or status |
| Patent |
U.S. 9,693,986 |
| Issue date |
July 4, 2017 |
| Patent type |
Method of treatment |
| Principal commercial product |
Vascepa, icosapent ethyl |
| Nominal patent expiry |
December 12, 2033 |
| FDA product |
Vascepa capsules |
| Relevant FDA supplement |
Cardiovascular-risk reduction indication approved December 2019 |
The patent was issued from the Vascepa cardiovascular-risk patent family and has an expiration date extending beyond the original 2012 triglyceride indication. The precise effective exclusivity date must be evaluated against any patent-term adjustment, terminal disclaimer, pediatric extension and other listed patents.
What is the Orange Book status of U.S. Patent 9,693,986?
U.S. Patent 9,693,986 was listed in the FDA Orange Book for Vascepa in connection with the cardiovascular-risk reduction indication. The listing gave the patent commercial relevance against ANDA applicants seeking approval for a product that included the protected indication.
The Orange Book listing did not convert the patent into a composition patent. It identified patent rights associated with an approved method of use. ANDA applicants could therefore pursue a paragraph IV certification or use a section viii statement to omit the patented indication, depending on the scope of the proposed label.
FDA approval of the product and Orange Book listing are separate from ultimate patent validity and infringement. The FDA does not adjudicate whether the claims are valid or infringed.
What Paragraph IV challenges affected Vascepa?
Vascepa attracted ANDA challenges after the 2019 cardiovascular indication approval. Hikma Pharmaceuticals and other generic applicants pursued approval of generic icosapent ethyl products.
The principal regulatory strategy was a skinny-label approach. A generic applicant could seek approval for the triglyceride-lowering indication while omitting the cardiovascular-risk indication associated with the 9,693,986 patent and related patents.
That strategy reduced the scope of the branded patent barrier. The commercial question became whether the generic label, product information, promotional conduct or distribution practices nevertheless encouraged use for the patented indication.
What patent litigation affected U.S. Patent 9,693,986?
Amarin asserted the cardiovascular-risk patent family, including U.S. Patent 9,693,986, against Hikma in the District of Delaware after Hikma filed an ANDA for generic icosapent ethyl.
The litigation focused on three issues:
- Whether the asserted claims were valid in view of earlier Vascepa and omega-3 clinical evidence.
- Whether Hikma’s carved-out label induced infringement.
- Whether generic prescribing and substitution could establish infringement despite omission of the cardiovascular indication.
The case demonstrated the limits of method-of-use patents against a skinny-label generic. A generic applicant can avoid direct label infringement by excluding the patented indication, although the risk remains if the label or conduct actively encourages the patented use.
The litigation outcome weakened the ability of the 9,693,986 patent to block generic entry for the nonpatented triglyceride indication. Generic icosapent ethyl products subsequently entered the U.S. market before the patent’s nominal expiration date.
How strong is the patent estate for Vascepa?
The Vascepa estate was strongest when evaluated as a portfolio rather than through U.S. Patent 9,693,986 alone.
| Estate component |
Strategic function |
| Cardiovascular-risk method patents |
Protect REDUCE-IT-related clinical use |
| Triglyceride-lowering method patents |
Protect earlier FDA-approved use |
| High-purity EPA composition patents |
Protect product composition |
| Formulation patents |
Protect capsule or delivery characteristics |
| Manufacturing patents |
Protect purification and production processes |
| Orange Book listings |
Support regulatory patent certifications and litigation |
U.S. Patent 9,693,986 has meaningful claim breadth because it covers the dose, triglyceride range and cardiovascular outcomes associated with the commercial cardiovascular indication. Its weaknesses are the need to prove clinical-use facts, the dependence on a statin-treated population and the availability of a skinny-label pathway.
The patent does not create a biosimilar barrier. Icosapent ethyl is a small-molecule active pharmaceutical ingredient, so competing products proceed through the ANDA pathway rather than the biosimilar pathway.
What generic entry risks exist?
Scenario 1: Triglyceride-only generic label
This is the lowest litigation-risk scenario for the 9,693,986 patent. The generic label excludes cardiovascular-risk reduction and limits approved use to triglyceride lowering.
Scenario 2: Full-label generic approval
A full label covering cardiovascular-risk reduction would create a direct patent-certification and infringement dispute. Entry would depend on patent validity, claim construction, settlement terms and any court-imposed stay.
Scenario 3: Skinny label with market substitution
This scenario creates indirect risk. Even if the cardiovascular indication is carved out, pharmacists, physicians and electronic prescribing systems may promote substitution. The legal result depends on the totality of the generic label and conduct.
Scenario 4: Off-label cardiovascular use
A generic manufacturer generally does not infringe merely because physicians prescribe an approved product off label. Exposure increases if the manufacturer markets, instructs or encourages the patented use.
Are there licensing deals associated with the patent?
The core commercial rights to Vascepa and its related patent portfolio were held and commercialized by Amarin. Amarin also entered regional commercialization and licensing arrangements for icosapent ethyl outside the United States, including arrangements involving Mochida Pharmaceutical, the original developer of the EPA product.
Those commercial agreements do not necessarily transfer U.S. patent ownership or determine U.S. infringement rights. The relevant questions are whether a license covers U.S. territory, whether it includes patent enforcement rights, and whether the agreement applies to the cardiovascular indication or only to specified markets.
What is the revenue exposure from the patent?
The patent’s revenue exposure was concentrated in the cardiovascular-risk indication approved after the REDUCE-IT outcomes trial. The patent did not protect all sales of Vascepa because the product also had a triglyceride-lowering indication and generic manufacturers could pursue that indication through a carved-out label.
The practical exposure therefore depended on:
- The proportion of prescriptions written for cardiovascular-risk reduction;
- The ability of generics to substitute under a skinny label;
- The enforceability of related cardiovascular-use patents;
- Reimbursement and formulary policies; and
- The extent of physician adoption of generic icosapent ethyl.
Key Takeaways
- U.S. Patent 9,693,986 is a method-of-use patent for cardiovascular-risk reduction with approximately 4 g/day of ethyl icosapentate.
- Claim 1 requires statin therapy, triglycerides of about 135 to 500 mg/dL and treatment for at least about two years.
- Claim 19 requires established cardiovascular disease but reduces the minimum treatment period to about four months.
- Dependent claims cover purity, dosage-unit count, baseline lipid values, washout restrictions and additional cardiovascular outcomes.
- The patent’s nominal expiration is December 12, 2033.
- It was linked to Vascepa’s cardiovascular-risk indication and Orange Book patent strategy.
- The patent does not protect a generic composition as such and does not create biosimilar exclusivity.
- Skinny-label ANDA strategies substantially reduced its ability to block generic approval for triglyceride lowering.
- The strongest infringement theory would require evidence that a generic manufacturer encouraged the patented cardiovascular use.
- Commercial protection depended on the full Vascepa patent portfolio, not U.S. Patent 9,693,986 alone.
Frequently Asked Questions
Is U.S. Patent 9,693,986 a composition patent?
No. It is a method-of-treatment patent. It protects specified clinical use of ethyl icosapentate in statin-treated patients.
Does the patent cover all 4 g/day icosapent ethyl treatment?
No. The patient must also satisfy the claimed triglyceride range and the relevant treatment and clinical-outcome limitations. Claim 19 also requires established cardiovascular disease.
Can a generic sell icosapent ethyl before December 2033?
Yes, if the generic obtains approval for an indication that does not infringe the listed method-of-use claims, such as a properly carved-out triglyceride-lowering indication, or if the patent is held invalid, unenforceable or not infringed.
Does a patient need to have coronary artery disease to fall within claim 1?
Not expressly. Claim 1 does not require established cardiovascular disease. Claim 19 and claim 20 do impose that requirement.
Do the claims cover EPA products containing DHA?
The independent claims require a composition comprising ethyl icosapentate. Claims 3 and 22 add a requirement that ethyl icosapentate constitute at least about 96 weight percent of all omega-3 fatty acids. A product containing material DHA could therefore raise additional claim-scope issues under those dependent claims.
References
- U.S. Patent and Trademark Office. (2017). U.S. Patent No. 9,693,986: Methods of reducing cardiovascular risk.
- U.S. Food and Drug Administration. (2019). FDA approves use of drug Vascepa to reduce risk of cardiovascular events in adults with elevated triglyceride levels.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
- U.S. Food and Drug Administration. (2024). Vascepa prescribing information. Amarin Pharma, Inc.
- U.S. District Court for the District of Delaware. (2020). Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc., patent litigation involving U.S. Patent Nos. 9,693,986 and related cardiovascular-risk patents.
